Yara Alenazi

We back ambitious founders building the future of enterprise technology. From inception through every flavour of pre-seed and seed, we provide the right resources at the right time, supporting founders as they scale globally. We’re people helping people dream, deliver, and win. The definition of enterprise software is evolving, and driving our investment strategy. Deep tech, fintech, healthcare, and hardware startups are shaping the next frontier of enterprise solutions—addressing immediate business needs while redefining industries. The globalization of early-stage funding is unlocking new opportunities, making geographic boundaries less relevant. We’ve embraced a borderless investment mindset, actively supporting founders across the UK, EU, U.S., and Israel. By fostering a more interconnected startup ecosystem, we help bold entrepreneurs build category-defining companies with global impact.

Recognized as 2024 Technology Pioneer by the World Economic Forum, and winner of the Top 100 Swiss Startup Award in 2024, DePoly is a Swiss cleantech company committed to tackling the plastic waste problem. Our cutting-edge recycling process converts plastics into high-quality raw materials without compromising their quality. Not only is it energy-efficient, but it also has the remarkable ability to handle even the most challenging streams of PET plastic and textiles, including mixed, dirty post-consumer and post-industrial waste that are traditionally considered unrecyclable. Our ambitious and dedicated team is made up of people challenging the status quo and striving for excellence, with a shared passion for making an impact!

Digitize patient journeys and support decision-making for patients and HCPs with API-first medical devices used by leading healthcare organizations.

Daye is a female-founded gynae health start-up on a mission to close the gender health gap for good. We started out with the invention of the world’s first pain-relieving tampon, designed to support the 90% of women who experience menstrual cramps. After helping over 75,000 women & AFAB individuals kick period pain to the curb, we launched our second generation tampon to facilitate the at-home detection of vaginal infections, STIs and HPV. Next, we want to develop solutions for under-served gynae health conditions like endometriosis, PCOS and menopause. Within the next five years, we will build an ecosystem where every woman can understand, monitor, and improve her health from her smartphone.

Truly meaningful medicine comes from breakthroughsin deeply understanding patient biology. We are building the world’s leading predictive simulation of patient biology. We will empower the biopharma industry by informing the right experiments that identify and validate disease driving hidden effects.

nyra health was founded with the idea of harnessing the power of AI to overcome limitations of current neuro-therapy, expand therapy content, and enable patients to achieve their full therapy potential. By combining artificial intelligence and evidence-based neurological research in an easy-to-use therapy software, we offer a holistic form of therapy at the cutting edge of science. Combined with our second product, nyra insights, nyra health offers an unprecedented view of the patients progress starting with the moment of diagnosis and accompanying them on every step of the patient journey.

HelloBetter is a European leader in the field of digital therapeutics (DTx) for mental health and a global pioneer in digital mental health research. Founded in 2015, HelloBetter has the strongest evidence base globally, with a total of 33 randomized controlled trials published in peer-reviewed journals. In Germany, six of their therapy programmes are part of the standard of care and as such available to 70+ million people for free as prescription digital therapeutics or DiGA. In 2022, HelloBetter entered the US market with its HelloGina brand which offers a sexual wellness program for people with vaginismus. In 2023, HelloBetter received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its digital therapeutic HelloBetter Panic.

Our Culture: At MMV, we’re a team of fair, dedicated investors and operators who put integrity, collaboration, and teamwork at the forefront of what we do. We believe in sharing ideas and perspectives and welcome the robust debate that comes with it. We approach our work knowing that trust and respect are earned. We look for this same culture in the founders and companies we back. Where We Invest: Our investment focus is on enterprise SaaS, climate technology, fintech, cybersecurity, and healthtech companies - areas that are fundamentally transforming business processes and consumer relationships. We invest in companies that bring differentiated technology solutions and scalable business models to drive enterprise-level innovation. When We Invest: We are a multistage investor, funding seed through growth stage rounds. We back teams that address real industry pain points and successfully convey the value of their solution to customers who are willing to pay. LP Value: Our sole limited partner is MassMutual, a Fortune 500 financial services firm with over $500B in assets under management. Our connection to MassMutual gives MMV’s portfolio companies access to a unique set of assets and capabilities within the firm, including a large real estate portfolio, renewable energy assets, and an internal network of later-stage equity and debt funds.

We back ambitious founders building the future of enterprise technology. From inception through every flavour of pre-seed and seed, we provide the right resources at the right time, supporting founders as they scale globally. We’re people helping people dream, deliver, and win. The definition of enterprise software is evolving, and driving our investment strategy. Deep tech, fintech, healthcare, and hardware startups are shaping the next frontier of enterprise solutions—addressing immediate business needs while redefining industries. The globalization of early-stage funding is unlocking new opportunities, making geographic boundaries less relevant. We’ve embraced a borderless investment mindset, actively supporting founders across the UK, EU, U.S., and Israel. By fostering a more interconnected startup ecosystem, we help bold entrepreneurs build category-defining companies with global impact.

Recognized as 2024 Technology Pioneer by the World Economic Forum, and winner of the Top 100 Swiss Startup Award in 2024, DePoly is a Swiss cleantech company committed to tackling the plastic waste problem. Our cutting-edge recycling process converts plastics into high-quality raw materials without compromising their quality. Not only is it energy-efficient, but it also has the remarkable ability to handle even the most challenging streams of PET plastic and textiles, including mixed, dirty post-consumer and post-industrial waste that are traditionally considered unrecyclable. Our ambitious and dedicated team is made up of people challenging the status quo and striving for excellence, with a shared passion for making an impact!

Digitize patient journeys and support decision-making for patients and HCPs with API-first medical devices used by leading healthcare organizations.

Daye is a female-founded gynae health start-up on a mission to close the gender health gap for good. We started out with the invention of the world’s first pain-relieving tampon, designed to support the 90% of women who experience menstrual cramps. After helping over 75,000 women & AFAB individuals kick period pain to the curb, we launched our second generation tampon to facilitate the at-home detection of vaginal infections, STIs and HPV. Next, we want to develop solutions for under-served gynae health conditions like endometriosis, PCOS and menopause. Within the next five years, we will build an ecosystem where every woman can understand, monitor, and improve her health from her smartphone.

Do you have a great research-based idea in planetary health or human health? Are you ready to bring your research out of the lab and into the economy? BioInnovation Institute (BII) offers life science researcher and entrepreneurs access to a vibrant life science community with 3500 square meter of advanced lab and office facilities, business acceleration programs, commercial support, funding opportunities and access to high-level mentoring and networks. We embrace every stage of a life science start-up, so whether the idea of pursuing entrepreneurship has briefly crossed your mind, or you already have a full business plan for your project, there is a place for you at BII. We are a Novo Nordisk Foundation Initiative, and we work for the benefit of human welfare and society.